The Latest Breaking News from ABT

Misty Copeland, the first Black woman promoted to principal dancer at American Ballet Theatre, returned to the stage at the 2026 Oscars with a performance that earned a standing ovation.

After a disappointing year at Abt, Mirko Bortolotti returns to Grasser as Lamborghini outlines the reasoning behind the switch involving its leading Austrian team.

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.